Press & Media

Press & Media

Kiromic BioPharma, Inc. welcomes Peter Hoang to its Board of Directors, who brings a wealth of experience in the biotechnology sector to his role as a Director for the company. Peter is currently President & Chief Executive Officer and a member of the Board of Directors of TapImmune (Nasdaq: TPIV) a clinical-stage immuno-oncology company with ongoing clinical trials at the Mayo Clinic and Memorial Sloan-Kettering Cancer Center. Prior to TapImmune, he served as the Senior Vice President of Business Development & Strategy at Bellicum Pharmaceuticals (Nasdaq: BLCM), a clinical stage immuno-oncology and cell therapy company developing small molecule-controllable gene-modified T cell-based therapeutics. Previously, Peter led the new venture formation and development effort as the Managing Director, Innovations in the Strategic Industry Ventures department for The University of Texas MD Anderson Cancer Center. In addition to his executive management experience leading publicly traded biotechnology companies, Peter has over 18 years of finance and deal-making experience in investment banking and venture capital, advising on over 100 transactions with an aggregate deal value of over $120 billion. Prior to MD Anderson, Peter was a senior investment banker, most recently as Managing Director and head of global healthcare mergers & acquisitions advisory for CIT Group (NYSE: CIT). He has also served in the M&A departments at Oppenheimer, J.P. Morgan, Merrill Lynch and Deutsche Bank.

Publications

Immunotherapy

  • Chiriva-Internati, M., & Bot, A. (2015). A New Era in Cancer Immunotherapy: Discovering Novel Targets and Reprogramming the Immune System. International Reviews Of Immunology, 34(2), 101-103. doi:10.3109/08830185.2015.1015888 http://www.ncbi.nlm.nih.gov/pubmed/25901856
  • Grizzi, F., Mirandola, L., Qehajaj, D., Cobos, E., Figueroa, J. A., & Chiriva-Internati, M. (2015). Cancer-Testis Antigens and Immunotherapy in the Light of Cancer Complexity. International Reviews Of Immunology, 34(2), 143-153. doi:10.3109/08830185.2015.1018418 http://www.ncbi.nlm.nih.gov/pubmed/25901859
  • Figueroa, J. A., Reidy, A., Mirandola, L., Trotter, K., Suvorava, N., Figueroa, A., & Chiriva-Internati, M. (2015). Chimeric Antigen Receptor Engineering: A Right Step in the Evolution of Adoptive Cellular Immunotherapy. International Reviews Of Immunology, 34(2), 154-187. doi:10.3109/08830185.2015.1018419 http://www.ncbi.nlm.nih.gov/pubmed/25901860
  • Mirandola, L., Figueroa, J. A., Phan, T. T., Grizzi, F., Kim, M., Rahman, R. L., Chiriva-Internati, M. (2015). Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets. Oncotarget, 6(5), 2812–2826. http://www.ncbi.nlm.nih.gov/pubmed/25739119
  • Chiriva-Internati, M., Mirandola, L., Yu, Y., Jenkins, M. R., Gornati, R., Bernardini, G., Cobos, E. (2011). Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy. J Immunother, 34(6), 490-499. doi:10.1097/CJI.0b013e31821ca76f http://www.ncbi.nlm.nih.gov/pubmed/21654522
  • Chiriva-Internati, M., Ferrari, R., Yuefei, Y., Hamrick, C., Gagliano, N., Grizzi, F., & Cobos, E. (2008). AKAP-4: a novel cancer testis antigen for multiple myeloma. British Journal Of Haematology, 140(4), 465-468. doi:10.1111/j.1365-2141.2007.06940.x http://www.ncbi.nlm.nih.gov/pubmed/18217892
  • Chiriva-Internati, M., Yu Y., Mirandola L., Jenkins M. R., Chapman C., Cannon M., Cobos E., Kast W. M. Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS One. 2010 May 12;5(5):e10471. doi: 10.1371/journal.pone.0010471. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868870/

BSK01™

  • Tawde, S. A., Chablani, L., Akalkotkar, A., D’Souza, C., Chiriva-Internati, M., Selvaraj, P., & D’Souza, M. J. (2012). Formulation and evaluation of oral microparticulate ovarian cancer vaccines. Vaccine, 30(38), 5675-5681. doi:10.1016/j.vaccine.2012.05.073 http://www.ncbi.nlm.nih.gov/pubmed/22750042

BSK02-ODP™

  • Chiriva-Internati, M., Pandey, A., Saba, R., Kim, M., Saadeh, C., Lukman, T., & Alalawi, R. (2012). Cancer Testis Antigens: A Novel Target in Lung Cancer. International Reviews Of Immunology, 31(5), 321-343. doi:10.3109/08830185.2012.723512 http://www.ncbi.nlm.nih.gov/pubmed/23083344
  • Pandey, A., Kurup, A., Shrivastava, A., Radhi, S., Nguyen, D. D., Arentz, C., Platonova, N. (2012). Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability. Int Rev Immunol, 31(5), 302-320. doi:10.3109/08830185.2012.723511 http://www.ncbi.nlm.nih.gov/pubmed/23083343
  • Cannon, M. J., Goyne, H., Stone, P. J., & Chiriva-Internati, M. (2011). Dendritic cell vaccination against ovarian cancer – tipping the Treg/Th17 balance to therapeutic advantage? Expert Opinion on Biological Therapy, 11(4), 441–445. http://doi.org/10.1517/14712598.2011.554812

KTI™

  • Pena, C., Mirandola, L., Figueroa, J. A., Hosiriluck, N., Suvorava, N., Trotter, K., Cobos, E. (2014). Galectins as therapeutic targets for hematological malignancies: a hopeful sweetness. Annals of Translational Medicine, 2(9), 87. http://doi.org/10.3978/j.issn.2305-5839.2014.09.14
  • Ebrahim, A. H., Alalawi, Z., Mirandola, L., Rakhshanda, R., Dahlbeck, S., Nguyen, D., Chiriva-Internati, M. (2014). Galectins in cancer: carcinogenesis, diagnosis and therapy. Annals of Translational Medicine, 2(9), 88. http://doi.org/10.3978/j.issn.2305-5839.2014.09.12
  • Mirandola, L., Yuefei, Y., Cannon, M. J., Jenkins, M. R., Rahman, R. L., Nguyen, D. D., & Chiriva-Internati, M. (2014). Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer. Gynecologic Oncology, 135(3), 573-579. doi:10.1016/j.ygyno.2014.09.021 http://www.ncbi.nlm.nih.gov/pubmed/25284038
  • Mirandola, L., Yuefei, Y., Cannon, M. J., Jenkins, M. R., Rahman, R. L., Nguyen, D. D., & Chiriva-Internati, M. (2014). Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer. Gynecologic Oncology, 135(3), 573-579. doi:10.1016/j.ygyno.2014.09.021 http://www.ncbi.nlm.nih.gov/pubmed/25284038
  • Mirandola, L., Nguyen, D. D., Rahman, R. L., Grizzi, F., Yuefei, Y., Figueroa, J. A., & Chiriva-Internati, M. (2014). Anti-Galectin-3 Therapy: A New Chance for Multiple Myeloma and Ovarian Cancer?. International Reviews Of Immunology, 33(5), 417-427. doi:10.3109/08830185.2014.911855 http://www.ncbi.nlm.nih.gov/pubmed/24801755
  • Mirandola, L., Yuefei, Y., Kitty, C., Jenkins, M. R., Cobos, E., John, C. M., & Chiriva-Internati, M. (2011). Galectin-3C Inhibits Tumor Growth and Increases the Anticancer Activity of Bortezomib in a Murine Model of Human Multiple Myeloma. Plos ONE, 6(7), 1-14. doi:10.1371/journal.pone.0021811 http://www.ncbi.nlm.nih.gov/pubmed/21765917